Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | NQO1 | P15559 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 4/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1837900 | 0.84 | ESR1 (0.42) | ALOX15LMNACYP2D6GAAHSD17B10 | |
| Ammonia Solution, Strong SCHEMBL10835340 | 0.81 | ALDH1A1 (0.44) | LMNASMN1; SMN2CYP1A2GAAHSD17B10 | |
| Ammonia Solution, Strong SCHEMBL5179938 | 0.79 | KMT2A (0.34) | LMNASMN1; SMN2PKMNPSR1GAA | |
| Ammonia Solution, Strong SCHEMBL5180373 | 0.79 | MCL1 (0.37) | LMNASMN1; SMN2CYP2D6GAAHSD17B10 | |
| SCHEMBL1841418 | 0.76 | MAOB (0.50) | ALOX15LMNASMN1; SMN2CYP1A2CYP2D6 | |
| Ammonia Solution, Strong SCHEMBL9328177 | 0.75 | TDP1 (0.53) | LMNASMN1; SMN2NPSR1GAANPC1 | |
| SCHEMBL29124826 | 0.75 | ALOX15 (0.34) | ALOX15NQO1SMN1; SMN2PKMNPC1 | |
| SCHEMBL7120045 | 0.75 | HTT (0.38) | ALOX15SMN1; SMN2NPSR1GAAHSD17B10 | |
| SCHEMBL6423330 | 0.74 | ESR1 (0.31) | ESR1ESR2 | |
| Ammonia Solution, Strong SCHEMBL5179076 | 0.74 | HCAR2 (0.51) | ALOX15LMNAGAACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025038920-A1 | HETEROARYL AMINE COMPOUNDS AND USES THEREOF | XENON PHARMACEUTICALS, INC. (CA) | 2025-02-20 | — | — | WO | disclosed |
| EP-4396354-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | Wave Life Sciences Ltd. (SG) | 2024-07-10 | — | — | EP | disclosed |
| WO-2024130218-A1 | STAPLED PEPTIDES AND METHODS THEREOF | FOG PHARMACEUTICALS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024020188-A2 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | AMYLYX PHARMACEUTICALS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2023220087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | AMYLYX PHARMACEUTICALS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220440-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023201095-A2 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-10-19 | — | — | WO | disclosed |
| EP-4240849-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | Wave Life Sciences Ltd. (SG) | 2023-09-13 | — | — | EP | disclosed |
| WO-2023096904-A2 | C-16 MODIFIED TRIOXACARCINS, ANTIBODY DRUG CONJUGATES, AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023075766-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-05-04 | — | — | WO | disclosed |
| EP-3307728-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | Dana Farber Cancer Institute, Inc. (US) | 2018-04-18 | — | — | EP | disclosed |
| WO-2018053373-A1 | USES OF SATL-INDUCIBLE KINASE (SIK) INHIBITORS FOR TREATING OSTEOPOROSIS | THE GENERAL HOSPITAL CORPORATION (US) | 2018-03-22 | — | — | WO | disclosed |
| WO-2018009544-A1 | BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2018-01-11 | — | — | WO | disclosed |
| WO-2017190038-A1 | ANALOGS OF YOHIMBINE AND USES THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2017-11-02 | — | — | WO | disclosed |
| WO-2016201370-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-12-15 | — | — | WO | disclosed |
| WO-2016154317-A2 | POLYMERS, HYDROGELS, AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2016-09-29 | — | — | WO | disclosed |
| US-20160264541-A1 | VITAMIN C PRODRUGS AND USES THEREOF | University of Florida Research Foundation, Inc.223 (US) | 2016-09-15 | — | — | US | disclosed |
| WO-2016115463-A1 | INHIBITORS OF PHOSPHOGLYCERATE DEHYDROGENASE (PHGDH) AND USES THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2016-07-21 | — | — | WO | disclosed |
| WO-2016081732-A1 | THIENOPYRIMIDINES AND USES THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2016-05-26 | — | — | WO | disclosed |
| WO-2009154697-A2 | DISC-1 PATHWAY ACTIVATORS IN THE CONTROL OF NEUROGENESIS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264541-A1 | VITAMIN C PRODRUGS AND USES THEREOF | PROC, ADH7, PNPO | ALOX15 754/4885NQO1 13/4885LMNA 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.